DSG2 and melanoma: Analysis of primary (stage I/II; n = 46) and metastatic (stage III/IV n = 25) tumors revealed DSG2 expression by S100+ melanoma cells in 39% of primary tumors and 24% of metastatic tumors, which was not a statistically significant difference (p = 0.294, Fisher's Exact test) (Figure 2B).